$ENSC

Ensysce Biosciences (ENSC) announced that its Chief Medical Officer, Richard Langford, will speak at an FDA hearing on September 14, 2026, about the future therapeutic use of psychedelic drugs. The hearing focuses on data standards and access considerations, aligning with Executive Order 14401. Ensysce, which acquired Cy Biopharma in August 2026, is developing psychedelic-based therapies for Complex Regional Pain Syndrome Type 1 (CRPS).

Ensysce Biosciences (NASDAQ: ENSC) completed enrollment in the final stage of its PF614-MPAR-102 clinical study, evaluating its opioid overdose-protection technology. The study, supported by the National Institute on Drug Abuse, aims to characterize the drug's protective profile. Ensysce's CEO called this a milestone in addressing opioid overdose risk. The company is a clinical-stage biotech developing pain management and CNS therapies. According to Ensysce, nearly 80,000 people in the U.S. die

Ensys (ENSC) received Nasdaq notices confirming compliance with the $2.5M equity rule but faces ongoing reviews on bid price and change-of-control requirements. The company was granted an extension to February 22, 2027, to address the bid-price issue and will submit an initial listing application due to its August acquisition of Cy.

Ensysce Biosciences (ENSC) has met Nasdaq's minimum equity requirement and requested a second 180-day grace period for its bid price. The company raised $21M from its Series C financing and awaits Nasdaq's confirmation. Delisting risk is reduced, but the second tranche is contingent on a clinical milestone.

Ensysce Biosciences raised $21M in the first tranche of its Series C financing, issuing 120,260 shares for a total $43M. The company meets Nasdaq equity rules and seeks a second 180-day grace period. It believes it has at least $2.5M in stockholders' equity, satisfying Nasdaq's requirements.

Ensysce Biosciences ended Q2 2026 with $676,704 in cash but secured $31M post-quarter from acquiring Cy Biopharma and related financings. The deal adds CY200, a neuroplastogenic candidate for CRPS, as the lead asset. Proceeds will fund CY200's Phase 2 trial and existing opioid programs. Ensysce's cash runway extends into late 2027, with a potential $38.6M tranche for 2028 if milestones are met. Q2 R&D expenses rose to $2.47M, widening the net loss to $2.57M.

Ensysce Biosciences (ENSC) completed a $77.2M private securities raise, with $38.6M contingent on future events. The offering involved equity and securities acquired via rights, with UBS and Cantor Fitzgerald as brokers. The company declined to disclose revenue.

Ensysce Biosciences (ENSC) Chairman Bob Gower increased his stake, acquiring 400,000 shares for $198,000 and converting notes into 508,614 shares. He agreed to vote in favor of merger-related proposals, including stock conversions and potential reverse splits to meet Nasdaq standards.

Ensysce Biosciences [ENSC] acquired Cy Biopharma and secured up to $77M in financing to advance CY200, a therapy for CRPS. The deal adds leadership and extends cash runway to late 2027, according to the company.

GOWER BOB G purchased 908,614 shares of Ensysce Biosciences, Inc. (ENSC) at an average of $0.49 ($0.48–$0.50, $0.44M total) across 2 trades over 2026-04-23 to 2026-08-07.